Could Lithium Change What We Know About Alzheimer’s?

In 2025, researchers at Harvard Medical School reported something unexpected about Alzheimer’s disease: tiny amounts of lithium naturally present in the brain may play a role in maintaining normal brain function.

Even more intriguing, they found that bioavailable lithium was already reduced in the brains of people with mild cognitive impairment, often an early stage on the path toward Alzheimer’s. In mice, deliberately lowering lithium in the brain produced many features associated with the disease. Restoring it with a compound called lithium orotate prevented some of those changes and reversed others.

Those results are exciting.

They are also very easy to overinterpret.

The research does not show that taking lithium orotate supplements prevents or treats Alzheimer’s in people. 

In fact, the doses sold as supplements are dramatically different from the tiny amounts used in the experiments.

So what did scientists actually discover, and why are researchers taking it seriously?

A familiar drug at an unfamiliar dose

Lithium is best known as a treatment for bipolar disorder. At psychiatric doses, it is a powerful medication that requires medical monitoring.

But lithium also occurs naturally in soil, food, drinking water, and the human body. Our ordinary exposure is tiny, varies with geology and diet, and has no established recommended intake.

The new research suggests that lithium may be more than an incidental environmental exposure. It may function as a physiologically active trace element in the brain, with consequences when its concentration falls too low.

That is a proposed biological role, not an accepted nutritional classification. Lithium is not currently recognized as an essential nutrient.

What is lithium orotate?

Lithium in medications and supplements comes as a salt: lithium ions paired with another ion, such as carbonate or orotate.

Prescription lithium is usually lithium carbonate. Lithium orotate pairs lithium with orotate, which is derived from orotic acid, a molecule involved in pathways cells use to make components of RNA and DNA.

Despite sounding similar, the compounds contain very different proportions of actual lithium. Lithium orotate is about 3.8% lithium by weight, so 120 mg contains roughly 4.6 mg of elemental lithium. Lithium carbonate is about 19% lithium, so the same 120 mg contains about 22.8 mg of elemental lithium.

Once dissolved, however, the lithium ion is chemically identical. So why would its partner matter?

Since the 1970s, advocates of lithium orotate have proposed that orotate helps carry lithium into cells of the brain. That mechanism has never been demonstrated in humans and remains unresolved. 

Interestingly, a 2023 mouse study found evidence for transport-dependent differences: inhibiting organic-anion transport abolished lithium orotate’s behavioral effect while leaving lithium carbonate’s effect intact. Whether this mechanism operates in humans, or matters at the much lower exposures relevant to Alzheimer’s research, is unknown.

The Harvard researchers found another possible reason the form matters.

Alzheimer’s plaques may act like lithium traps

The researchers measured 27 metals in donated brain tissue from people who had remained cognitively healthy, developed mild cognitive impairment, or developed Alzheimer's.

Lithium stood out.

Of all 27 metals, only lithium was significantly reduced in the prefrontal cortex at the mild cognitive impairment stage. The cerebellum, a region relatively spared by Alzheimer's, showed no such reduction. Serum lithium levels did not differ significantly across the groups.

Then the researchers discovered something important: lithium was concentrated inside amyloid plaques, while lithium in the surrounding, more bioavailable brain tissue was reduced.

They proposed that electrostatic attraction helps explain this sequestration. Lithium is positively charged, while aggregated amyloid provides negatively charged binding sites. Laboratory experiments supported the model.

Lower lithium outside plaques was also associated with poorer memory and cognition.

But these human observations could not answer a crucial question: Does losing available lithium contribute to disease, or is it simply a consequence of Alzheimer's?

Testing cause and effect in mice

To investigate, the researchers fed mice a diet selectively depleted of lithium. Brain lithium fell by roughly half, reproducing the kind of depletion seen in the human tissue.

The consequences were broad.

The mice accumulated more amyloid and abnormally phosphorylated tau. Their microglia, the brain's immune cells, became more inflammatory and worse at clearing amyloid. They lost synaptic connections and showed deterioration of myelin, the insulation around nerve fibers. Their memory also worsened.

Even ordinary aging mice without Alzheimer's-related genetic modifications developed memory impairment when lithium was depleted.

One mechanism involved GSK3β, an enzyme long implicated in Alzheimer's biology. Lithium deficiency increased its activity, while experimental drugs that blocked GSK3β reversed many of the resulting abnormalities.

The animal work therefore strengthened the possibility that lithium depletion isn’t merely a byproduct of disease, but perhaps it can itself drive disease-like changes.

Why lithium orotate behaved differently

If amyloid traps lithium, the researchers reasoned that a lithium salt less prone to ionization might be less susceptible to sequestration.

They tested 16 lithium salts. Lithium orotate was the least prone to ionizing.

At matched doses of elemental lithium, lithium carbonate accumulated preferentially with plaques, while lithium orotate increased lithium in the surrounding brain tissue.

The biological results were interesting. In Alzheimer’s-model mice, lithium orotate reduced plaque burden by roughly 70% in one model, reduced abnormal tau-related pathology and inflammation, restored markers of synaptic and myelin health, and largely reversed memory deficits. Lithium carbonate at the same elemental lithium dose did not produce comparable effects.

Within this study, the apparent advantage of orotate came from reduced amyloid binding. That doesn't rule out separate differences in how lithium orotate is transported.

The dose is the detail often missed

The effective concentration was just 0.03 mg of elemental lithium per liter of drinking water.

The researchers deliberately chose a dose intended to keep lithium in the blood and brain within the physiological range they had measured in untreated animals and aging humans. The goal was physiological replacement rather than pharmacologic exposure.

Commercial supplements operate on a very different scale. One product documented in the medical literature contained 120 mg of lithium orotate per tablet, about 4.6 mg of elemental lithium.

Those numbers cannot be converted directly into equivalent human doses, and there is currently no established human lithium-replacement target.

The research shows that restoring physiological lithium may have a protective effect in some areas on mice. It does not show that commercial lithium orotate supplements benefit humans.

A large Danish observational study offers some supporting, but inconclusive, human evidence. Dementia incidence differed with long-term lithium exposure in drinking water, with lower incidence at the highest exposure category. But the relationship was nonlinear, and researchers could not exclude other differences between the communities studied.

What do human trials tell us?

Completed human trials in this area have studied lithium carbonate or conventional lithium formulations, not lithium orotate.

Results have been mixed. Some studies found little benefit, while several using lower lithium exposures reported potentially favorable cognitive or biomarker findings.

The latest evidence came from the 2026 LATTICE trial. Researchers randomized older adults with mild cognitive impairment to low-dose lithium carbonate or placebo for two years.

None of the trial's six coprimary outcomes met its prespecified significance threshold. One measure of verbal memory declined more slowly with lithium, but the difference did not meet that threshold.

There was another complication: many participants did not have biomarker evidence of the amyloid pathology central to the Alzheimer's hypothesis.

The investigators therefore described the trial primarily as establishing the feasibility and safety of conducting a larger study, not as proving lithium slows cognitive decline.

A trial of lithium orotate itself has now been registered at Johns Hopkins. As of August 2026, it has not yet begun recruiting, with results not expected until 2029.

Why researchers are advising patience

The appropriate human dose of lithium orotate is unknown.

Bruce Yankner, senior author of the Nature study, has said that effective and safe doses need to be established in people before lithium orotate can be recommended.

There are good reasons for that caution.

Lithium can affect kidney and thyroid function, and its concentration can rise with dehydration or interactions with medications including some diuretics, NSAIDs, and blood-pressure drugs.

Most clinical guidance about serum lithium concentrations, toxicity, and monitoring comes from decades of experience with prescription lithium, particularly lithium carbonate. There is no comparably validated monitoring framework for lithium orotate.

Lithium orotate is also sold as a dietary supplement, meaning it does not undergo premarket approval for safety or efficacy.

Published human safety experience is sparse. In one case report, an 18-year-old who intentionally took 18 lithium orotate tablets developed nausea, vomiting, and mild tremor. Her symptoms resolved after supportive care and observation. The authors classified the episode as mild acute lithium toxicity.

Where this leaves things

The new research supports an interesting possibility: naturally occurring lithium may be part of the brain’s normal protective machinery, and Alzheimer's pathology may disrupt that balance early in the disease.

The combination of human brain evidence and causal animal experiments makes the hypothesis an interesting one to watch.

But the gap between that discovery and the supplement aisle remains wide.

We don’t know the appropriate human dose. We don't know whether lithium orotate slows Alzheimer's in people. And the first clinical trial designed to begin answering those questions has not yet produced results.

For now, this is research worth watching, not a treatment worth self-prescribing.

This article is for informational and educational purposes and is not medical advice. Lithium can interact with medications and affect kidney and thyroid function. Anyone considering supplementation should speak with a qualified clinician.